Dynavax Technologies Corp. (NASDAQ:DVAX)’s share price traded up 2.9% on Thursday . The stock traded as high as $15.80 and last traded at $15.47, with a volume of 337,198 shares traded. The stock had previously closed at $15.04.

Several equities analysts recently weighed in on the stock. Zacks Investment Research downgraded shares of Dynavax Technologies Corp. from a “hold” rating to a “sell” rating in a report on Tuesday, May 31st. Cowen and Company reaffirmed a “buy” rating and set a $60.00 price objective on shares of Dynavax Technologies Corp. in a research note on Thursday, April 28th. Royal Bank Of Canada cut shares of Dynavax Technologies Corp. from an “outperform” rating to a “sector perform” rating and dropped their price objective for the stock from $48.00 to $17.00 in a research note on Wednesday, April 27th. Finally, JPMorgan Chase & Co. cut shares of Dynavax Technologies Corp. from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $29.00 to $22.00 in a research note on Wednesday, April 27th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $32.20.

The company has a 50 day moving average price of $14.89 and a 200 day moving average price of $18.19. The stock’s market cap is $589.74 million.

Dynavax Technologies Corp. (NASDAQ:DVAX) last posted its earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.63) by $0.07. The company earned $942 million during the quarter, compared to analysts’ expectations of $627 million. Equities analysts forecast that Dynavax Technologies Corp. will post ($2.90) earnings per share for the current fiscal year.

In other Dynavax Technologies Corp. news, CEO Eddie Gray bought 2,750 shares of the firm’s stock in a transaction that occurred on Friday, May 20th. The stock was purchased at an average price of $15.57 per share, for a total transaction of $42,817.50. Following the completion of the purchase, the chief executive officer now directly owns 5,050 shares in the company, valued at $78,628.50. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

A number of large investors have recently modified their holdings of DVAX. Swiss National Bank boosted its stake in shares of Dynavax Technologies Corp. by 5.7% in the fourth quarter. Swiss National Bank now owns 48,528 shares of the biopharmaceutical company’s stock worth $1,172,000 after buying an additional 2,600 shares in the last quarter. Trexquant Investment LP boosted its stake in shares of Dynavax Technologies Corp. by 14.5% in the fourth quarter. Trexquant Investment LP now owns 70,200 shares of the biopharmaceutical company’s stock worth $1,696,000 after buying an additional 8,911 shares in the last quarter. Finally, California State Teachers Retirement System boosted its stake in shares of Dynavax Technologies Corp. by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 67,895 shares of the biopharmaceutical company’s stock worth $1,640,000 after buying an additional 1,177 shares in the last quarter.

Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.